SGEN — Seagen Share News
0.000.00%
Last trade - 00:00HealthcareBalancedLarge Cap
- $43.15bn
- $41.92bn
- $1.96bn
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint (updated)
Genmab, Seagen say phase three of innovaTV 301 trial met primary endpoint
Brief: Genmab, Seagen Announce That Tivdak Met Its Primary Endpoint Of Improved Overall Survival In Patients With Recurrent Or Metastatic Cervical Cancer Compared To Chemotherapy
U.S. STOCKS ON THE MOVE-Seagen, Dell, Rivian
Pfizer, Seagen rise after FTC nod for Amgen's Horizon deal
Refinitiv Newscasts - Trading at Noon: Stocks mixed ahead of Fed minutes; Target jumps
Seagen's breast cancer therapy meets main goal in late-stage study (updated)
Brief: Seagen Phase 3 Trial Of Tukysa (Tucatinib) In Combination With Antibody-Drug Conjugate ADO-Trastuzumab Emtansine Meets Primary Endpoint
Seagen's breast cancer therapy meets main goal in late-stage study
Brief: Skanska Signs Contract With Seagen To Build Facility
Seagen Inc reports results for the quarter ended in June - Earnings Summary
Brief: Seagen Q2 EPS USD -1.13
Pfizer considers cost cuts as demand for COVID products wanes (updated)
Seagen Inc expected to post a loss of 81 cents a share - Earnings Preview
What to Watch in the Day Ahead - Tuesday, Aug. 1
What to Watch in the Week Ahead and on Monday, July 31
US FTC seeks additional info on Pfizer's proposed takeover of Seagen (updated)
US FTC seeks additional info on Pfizer's proposed takeover of Seagen
Brief: Seagen Says On July 14, Co And Pfizer Received Request For Additional Information And Documentary Materials From FTC In Connection With Review Of Merger